Gawrieh S, Noureddin M, Loo N, et al. - This study was attempted to assess the effectiveness and safety of saroglitazar (a novel dual peroxisome proliferator activated receptor α/γ agonist) in patients with non‐alcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in this randomized controlled clinical trial. Researchers included 106 patients with NAFLD/NASH with ALT ≥ 50 U/L at baseline and body mass index ≥ 25 kg/m2 randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The data exhibited that in participants with NAFLD/NASH, saroglitazar 4 mg significantly improved ALT, liver fat content, insulin resistance, and atherogenic dyslipidemia.